Supplemental Materials for JAAD Publication JAAD-D-22-02295, A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Ivarmacitinib (SHR0302) in Adult Patients with Moderate to Severe Alopecia Areata

These are supplemental data sets to the JAAD publication entitled "A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Ivarmacitinib (SHR0302) in Adult Patients with Moderate to Severe Alopecia Areata".本数据集为发表于JAAD（《美国皮肤病学会杂志》，Journal of the American Academy of Dermatology）、题为《一项评估伊马塞替尼（Ivarmacitinib，SHR0302）用于中重度斑秃成年患者的有效性与安全性的随机双盲安慰剂对照II期临床试验》的学术论文的补充数据集。